XML 19 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:    
Net income (loss) $ (872,000) $ 2,739,000
Adjustments to reconcile net income (loss) to net cash:    
Stock compensation expense 93,000 89,000
Foreign exchange loss (gain) (7,000) 41,000
Depreciation and amortization 299,000 311,000
Deferred income taxes 533,000 (2,730,000)
Non-cash R&D services 163,000 38,000
Other 44,000 35,000
Other changes in assets and liabilities:    
Accounts receivable, net (333,000) (374,000)
Inventories (198,000) (280,000)
Costs in excess of billings and unbilled receivables 88,000 249,000
Prepaid expenses and other assets 51,000 189,000
Accounts payable (483,000) (99,000)
Accrued expenses and other liabilities (236,000) (790,000)
Deferred revenue (95,000) 2,000
Net cash from operating activities (953,000) (580,000)
Cash flows from investing activities:    
Purchases of property, plant and equipment (609,000) (91,000)
Purchase of intangibles (16,000) (20,000)
Net cash from investing activities (625,000) (111,000)
Cash flows from financing activities:    
Proceeds from issuance of common stock 4,000 4,000
Principal payments on capital leases (26,000) (28,000)
Proceeds from (payments of) equipment line of credit, net 281,000 0
Proceeds from (payments of) bank and subordinated debt, net (141,000) (219,000)
Net cash from financing activities 118,000 (243,000)
Effect of exchange rates on cash and cash equivalents 6,000 (49,000)
Net change in cash and cash equivalents (1,454,000) (983,000)
Cash and cash equivalents, beginning 2,415,000 2,607,000
Cash and cash equivalents, ending 961,000 1,624,000
Supplemental disclosures of cash flow information:    
Cash paid during the year for: Interest 37,000 47,000
Cash paid during the year for: Tax payments (refunds) 4,000 0
Non cash activities:    
Recapitalization of Xcede - conversion of non controlling notes payable to preferred stock 0 3,104,000
Subsidiary stock options issued to settle liabilities 0 82,000
Subsidiary debt issued to fund research activities $ 0 $ 500,000